On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

“Intra-Bone” Gene Therapy Reduced Transfusion Need in Patients With Beta-Thalassemia

Gene therapy could represent an alternative to hematopoietic stem cell transplantation (HCT) – the only curative therapy for beta-thalassemia – and may offer several...

Two Versus Three Cycles of Consolidation Therapy for Patients With AML

Patients with core-binding factor acute myeloid leukemia (CBF-AML) who received only two cycles of consolidation chemotherapy experienced similar rates of relapse-free survival (RFS) and...

Catching Up With First-Time Attendees

In December 2017, we introduced you to two first-time ASH annual meeting attendees: Kelly Schoenbeck and Rahul Vedula. We checked in with them to...

Could Adding Sotatercept to Ruxolitinib Improve MPN-Associated MF and Anemia?

The JAK1 inhibitor ruxolitinib is the only therapy approved by the U.S. Food and Drug Administration for myelofibrosis (MF), but it often worsens anemia,...

Will Replacing Bleomycin With Brentuximab Vedotin Revolutionize Frontline Hodgkin Lymphoma Treatment?

For patients with advanced-stage Hodgkin lymphoma (HL), eliminating bleomycin (and its associated risks of pulmonary toxicity) from the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)...

Newly Approved Drugs in ALL and NHL: How to Use Them in Practice

In 2017, the U.S. Food and Drug Administration (FDA) approved several therapies for the treatment of hematologic malignancies, marking the first chimeric antigen receptor...

Interim Results from the First-in-Human Trial of Antibody Drug Conjugate ADCT-402 in B-Cell Malignancies

In a first-in-human trial of loncastuximab tesirine, the CD19-targeting antibody drug conjugate (ADC) appeared to have manageable toxicity and encouraging efficacy as a single...

Phase I Trial Shows “Exciting” Results With Avapritinib in Advanced Systemic Mastocytosis

The oral KIT D816V inhibitor avapritinib (formerly known as BLU-285) could provide an alternative treatment option for patients with advanced systemic mastocytosis (SM), including...

Transfusion Dependence Delays Hospice Enrollment in Patients With Leukemia

Because many hospice organizations disallow life-extending transfusion support, transfusion dependence (TD) can pose a substantial barrier to enrolling patients with leukemia in palliative or...

ZUMA-1 at One Year: Durable Responses to Axicabtagene Ciloleucel in Patients With Aggressive NHL

In October 2017, axicabtagene ciloleucel became the second chimeric antigen receptor (CAR) T-cell therapy approved by the U.S. Food and Drug Administration, and the...
Advertisement

Current Issue

January 2018, Volume 4, Issue 1

This issue features a look at the misconceptions that challenge the viability of the blood-banking system, highlights from the 2017 ASH Annual Meeting, and more.